You might remember Tom Price as the former HHS secretary who was forced to resign after using public funds for private chartered flights. But before that controversy ended his political career, Price was a Georgia Republican who was also controversial for his investments.
Price, regular readers may recall, invested in an Australian biomedical firm, Innate Immunotherapeutics, and then sponsored legislation that sent the company’s stock higher, making his investment far more valuable.
But Price wasn’t alone. Rep. Chris Collins (R-N.Y.), one of Donald Trump’s key congressional allies, was an even bigger investor in Innate Immunotherapeutics — indeed, the New York Republican sits on the company’s board — and Collins also took the lead on pushing legislation that benefited the company.
The Daily Beast moved the ball forward yesterday, reporting that Collins has sponsored “several bills” that would have benefited the company he’s invested in, while also “trying to make changes to a government program that would save the company millions of dollars if its drug is approved by the FDA.”
Collins’s office says he doesn’t believe his bills represent a conflict of interest, but he is already accused by independent Office of Congressional Ethics of violating House ethics rules and U.S. securities law for his dealings with the drug company.









